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Abstract
Large-scale application of alginate-poly-L-lysine (alginate-PLL) capsules used for microencapsulation of living cells is
hampered by varying degrees of success, caused by tissue responses against the capsules in the host. A major cause is
proinflammatory PLL which is applied at the surface to provide semipermeable properties and immunoprotection. In this
study, we investigated whether application of poly(ethylene glycol)-block-poly(L-lysine hydrochloride) diblock copolymers
(PEG-b-PLL) can reduce the responses against PLL on alginate-matrices. The application of PEG-b-PLL was studied in two
manners: (i) as a substitute for PLL or (ii) as an anti-biofouling layer on top of a proinflammatory, but immunoprotective,
semipermeable alginate-PLL100 membrane. Transmission FTIR was applied to monitor the binding of PEG-b-PLL. When
applied as a substitute for PLL, strong host responses in mice were observed. These responses were caused by insufficient
binding of the PLL block of the diblock copolymers confirmed by FTIR. When PEG-b-PLL was applied as an anti-biofouling
layer on top of PLL100 the responses in mice were severely reduced. Building an effective anti-biofouling layer required
50 hours as confirmed by FTIR, immunocytochemistry and XPS. Our study provides new insight in the binding requirements
of polyamino acids necessary to provide an immunoprotective membrane. Furthermore, we present a relatively simple
method to mask proinflammatory components on the surface of microcapsules to reduce host responses. Finally, but most
importantly, our study illustrates the importance of combining physicochemical and biological methods to understand the
complex interactions at the capsules’ surface that determine the success or failure of microcapsules applicable for cell-
encapsulation.
Citation: Spasojevic M, Paredes-Juarez GA, Vorenkamp J, de Haan BJ, Schouten AJ, et al. (2014) Reduction of the Inflammatory Responses against Alginate-Poly-
L-Lysine Microcapsules by Anti-Biofouling Surfaces of PEG-b-PLL Diblock Copolymers. PLoS ONE 9(10): e109837. doi:10.1371/journal.pone.0109837
Editor: Xiaoming He, The Ohio State University, United States of America
Received July 13, 2014; Accepted September 3, 2014; Published October 27, 2014
Copyright:  2014 Spasojevic et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This work was supported by a project from The Kollf institute and the Juvenile Diabetes research foundation. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: P.de.Vos@umcg.nl
Introduction
Microencapsulation of therapeutics cells is a promising
approach for treatment of endocrine disorders such as anemia
[1], dwarfism [2], hemophilia B [3], kidney [4] and liver [5]
failure, pituitary [6] other central nervous system insufficiencies
[7], and diabetes [8]. The semipermeable membrane allows for
diffusion of nutrients and therapeutics, whereas the cells are
protected from the immune system. This approach eliminates the
necessity for immunosuppression and allows for xenografting.
Xenografting may contribute to solving donor shortage.
Alginate-poly-L-lysine capsules have frequently been applied for
microencapsulation of pancreatic islets [8]. Alginates are natural,
unbranched polysaccharides composed of two monomer units, b-
D-mannuronic acid (M) and its C-5 epimer, a-L-guluronic acid
(G), connected by 1R4 linkages. They gel under physiological
conditions without involvement of any toxic compounds such as
harmful solvents. Many groups apply poly-L-lysine (PLL) to
reduce the pore size and to provide immunoprotection [9,10].
Normally unbound PLL is immunogenic [11]; however, to
circumvent host responses against PLL, the microcapsules are
ionically cross-linked with alginate to induce complexes of
superhelical cores of alginate and PLL at the capsule’s surface
[12,13]. But this process is not straightforward [14,15]. Minor
changes in the procedure can result in inadequate binding of
proinflammatory PLL with strong immune reactions in the host as
a consequence [13,14,16–18]. This was shown recently by our
group in a comparison study of the in vivo behavior of a series of
alginate-PLL capsules that differed only 10% in G-content. The
alginate with higher G-content underwent changes in vivo, which
resulted in the release of proinflammatory PLL followed by a
strong tissue response [17].
Many different polycations have been proposed to substitute
PLL, designed to provide immunoprotection on alginate matrixes
for cell encapsulation [19–22]. Among them are chitosan [20], poly-
L-ornithine [21,23], poly-D-lysine [22] and diblock copolymers
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[24]. Often, however, new issues are introduced with these
alternatives to PLL, leading again to severe inflammatory responses
in vivo [19]. Partly, this is due to lack of knowledge about how the
polyamino acids interact with alginate [14,23,25–27], but it is also
due to the enormous lab-to-lab variations in successful formation of
immunoprotective membranes [28,29]. These issues led to our
current proposal to design means for making capsule’s surfaces
more biocompatible, while still using PLL for providing immuno-
protection because of its well known binding ability to alginate.
Introducing diblock copolymers is, theoretically, such an approach,
but has been difficult to achieve on the surface of cell-containing
hydrophilic capsules. Many procedures to build membranes require
harsh chemicals, eliminating them as options as only cell-friendly
approaches may be applied to avoid loss of cells. The use of cell-
friendly approaches is especially important when cell-sources from
rare cadaveric donors are applied such as pancreatic islets for the
treatment of diabetes [30]. Any loss of tissue is unacceptable in these
types of applications. Here we studied the ability of PEG-b-PLL
copolymers to reduce inflammatory responses. The copolymer can
be applied as a complete substitute for PLL or as an additional layer
on top of a preexisting proinflammatory PLL layer. The PEG-b-
PLL copolymers can be bound to the surface of alginate without the
application of chemicals that interfere with tissue viability. The
PLL-block interacts ionically with the negatively charged alginate-
core. The other block, polyethylene glycol (PEG), provides a
biocompatible protecting layer on the surface of the capsules.
This study was designed to investigate the application of diblock
copolymers in two manners. The first application was as a
complete substitute for PLL, forming an immunoprotective
membrane as previously suggested [24]. The other application
was as an anti-biofouling layer on top of an immunoprotective
PLL layer. We choose to use PLL100 to study the masking effects of
the PEG-b-PLL copolymer. PLL100 provokes strong inflammatory
responses due to incomplete binding to alginate as will be
demonstrated in this study. The adsorption kinetics of the diblock
copolymers on the alginate surface was studied by FTIR. The
binding of diblock copolymers and surface properties in the
absence and presence of the diblock copolymers were character-
ized by FTIR and XPS, respectively. Host responses were studied
after implanted in the peritoneal cavity of balb/c mice.
Materials and Methods
Materials
Intermediate-G sodium alginate was obtained from ISP
Alginates (UK). Poly-L-lysine hydrochloride (PLL100)
(Mn = 16 kg/mol) and methoxy-poly(ethylene glycol)-block-
poly(L-lysine hydrochloride) (PEGx-b-PLLy) (x = 454,
Mn = 20 kg/mol; y = 50 or 100, Mn = 8 or 16 kg/mol;
PDI = 1.2) were purchased from Alamanda Polymers (USA).
Streptavidin fluorescein isothiocyanate (FITC) and Rabbit anti-
PEG biotin were purchased from DakoCytomation (Denmark)
and Bio-Connect B.V. (The Netherlands), respectively.
Deposition of alginate films on silicon wafers
Prior to applying alginate coatings, double-side polished silicon
wafers (Topsil Semiconductor Materials A/S, Frederikssund,
Denmark 1000615 mm thick) were cleaned by subsequent
ultrasonication in dichloromethane, methanol, and acetone for
10 minutes. Residual organic contaminants were removed by UV-
ozone treatment using an UV-ozone photoreactor PR-100
(Uvikon) for 60 minutes. Due to this treatment, the hydrophilicity
of the exposed surface increases. Immediately after cleaning an
alginate layer was applied on the surface.
Purified sodium alginate was dissolved in Krebs-Ringer-Hepes
buffer (KRH, 220 mOsm) to give a 3.4 w/v % solution. The final
alginate layer was obtained by dipping the recently cleaned and
vertically aligned silicon wafers (1.561.0 cm) into the 3.4 w/v %
alginate solution at a constant rate of 1 cm/min. The withdrawal
rate was 10 cm/min. Silicon wafers coated with sodium alginate
were placed into 100 mM CaCl2 buffer after which alginate was
allowed to cross-link with calcium overnight. Before the alginate
gels were exposed to PLL100 and copolymer solution, transmission
FTIR spectra of the dry alginate layers were recorded.
The binding of copolymers to calcium alginate-PLL100 layers
was studied as follows. After washing in KRH (containing 2.5 mM
CaCl2) for 1 minute, one portion of alginate gel layers was
incubated in PLL100 solution (in KRH containing 2.5 mM CaCl2,
PLL concentration 6.2561028 mol/ml) for 10 minutes. Subse-
quently the layers were washed four times with KRH, dried under
a filtered air stream and measured by FTIR. Alginate-PLL100 and
the rest of alginate gel layers were incubated in copolymer
solutions (in KRH containing 2.5 mM CaCl2, copolymer concen-
tration 3.5561028 mol/ml). After certain time intervals, the
wafers were removed from the copolymer solution, washed four
times with KRH, dried under a filtered air stream and measured
by FTIR. Subsequently the wafers were returned to the copolymer
solution in order to continue the adsorption process and to
determine the saturation point.
Transmission Fourier transform infrared spectroscopy
The calcium alginate layers, as well as the layers after the pre-
treatment with PLL100 and/or the adsorption of PEG-b-PLL
copolymers, were studied by transmission FTIR. Measurements
were performed under vacuum on a Bruker IFS 66 v/S
spectrometer equipped with a DTGS detector and OPUS software
package. A sample shuttle accessory was used for an interleaved
sample and background scanning. A clean silicon wafer was used
as a reference. All spectra are averages of 66120 scans measured
at a resolution of 4 cm21.
The adsorption of PLL100 and the copolymer was followed by
analyzing the increase in the surface area associated with
asymmetric and symmetric C-H stretching vibrations (3000 to
2800 cm21). In order to quantify the PLL- and copolymer-content
on the calcium alginate, the surface area of the symmetric and
asymmetric C-H stretching vibrations was determined. This value
was reduced for the surface area corresponding to the C-H
stretching vibrations of calcium alginate. Thus, the content of
polymer attached to calcium alginate for each time point was
obtained. These values were plotted as a function of time and the
saturation point was determined as the starting point of the
plateau.
Microcapsules formation
Only intermediate-G alginates were used and were purified
according to literature procedures [31]. Subsequently, capsules
were produced based on a previously described procedure with
some modifications [32,33]. In some experiments cells were
included. To this end, human insulin producing CM cells were
cultured in RPMI (Gibco, Breda, The Netherlands) containing
60 kg/mL gentamicin and 10% heat-inactivated fetal calf serum
(FCS) [34]. CM cells were always used between passage numbers 5
and 20. The cells were mixed at a concentration of 16106/ml with
3.4 w/v % sodium alginate solution. The cell containing or empty
capsules were formed by converting the 3.4 w/v % sodium
alginate solution into droplets using an air-driven generator [35].
The diameter of the droplets was controlled by a regulated airflow
around the tip of needle. Alginate droplets were transformed to
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rigid alginate beads by gelling in a 100 mM CaCl2 solution for at
least 10 minutes. The beads were washed with KRH (containing
2.5 mM CaCl2) for 1 minute. One portion of the beads was coated
with the PEG-b-PLL copolymer for one hour and subsequently
washed four times with KRH. Another portion of the beads was
coated with PLL100 for 10 minutes (PLL100 solution in 310 mOsm
KRH containing 2.5 mM CaCl2, PLL concentration
6.2561028 mol/mL), subsequently washed four times with
KRH and in the last step the capsules were coated with the
PEG-b-PLL copolymer for as long as required to obtain a
saturated surface as monitored by FTIR. Finally, the capsules were
washed 3 times with 310 mOsm KRH containing 2.5 mM CaCl2
and stored in this buffer. The diameters of capsules and beads
were measured with a dissection microscope (Bausch and Lomb
BVB-125, and 31–33–66) equipped with an ocular micrometer
with an accuracy of 25 pm. The final diameter of the capsules was
600 mm.
FITC labelling of microcapsules
Fluorescent labeling of microcapsules is a multi-step procedure.
Primary antibody was added to a 10% solution of normal rabbit
serum in phosphate buffered saline (PBS). The optimal primary
antibody concentration was investigated and found to be when the
antibody was diluted 500 times. To stain end-groups of PEG,
100 ml of this PBS solution was added to an eppendorf cup with
approximately 20 capsules and left to shake for 1 hour at room
temperature. The capsules were washed several times with PBS
and subsequently incubated in PBS solution of streptavidin FITC
(streptavidin FITC/PBS = 1/100) for 30 minutes in the dark.
Finally, the capsules were washed several times with PBS,
transferred onto a glass slide and studied at room temperature
with a Leica TCS SP2 AOBS confocal microscope (50 w Hg lamp,
HC PL APO CS 106/0,30 dry, working distance 11 mm, 5(6)-
FITC; FITC excitation wavelength 494 nm, FITC emission
wavelength 518 nm). Confocal analyses were performed using
the Imaris664 version 7.6.4 software.
Testing cell viability
Viability of encapsulated cells was test using a LIVE/DEAD
Cell Viability/Cytotoxicity assay Kit from InvitroGen, Life
Technologies (New York, USA). Encapsulated cells were incubat-
ed for 30 min with Calcein AM (1 mM) and Ethidium Bromide
(EB) (2 mM) at room temperature avoiding light. After incubation,
the encapsulated cells were washed five times with KRH.
Fluorescent confocal microscopy was measured at an emission
wavelength of 517 nm (Calcein AM) and 617 nm (EB) using a
Leica TCS SP2 AOBS confocal microscope (Wetzlar, Germany)
equipped with an objective HC PL APO CS 106/0,30, dry
immersion, and working distance of 11 mm. Data was analyzed
using Imaris664 version 7.6.4 software. The number of dead and
live cells was quantified by counting at least 500 cells per batch.
The fraction of dead cells was expressed as the percentage of the
total number of counted cells.
Diffusion characteristics
Permeability of capsules was studied using dextran-f samples of
10, 20, 40, 70, 110, or 150 kg/mol (TdB Consultancy AB,
Sweden) as previously described [36–38]. For each dextran,
approximately 50 capsules were placed on a microscope slide
exposed to 200 mL of 0.1% dextran-f in Krebs Ringer Hepes,
promptly covered with a glass coverslip and examined by
fluorescence microscopy (Leica TCS SP2 AOBS confocal micro-
scope). These permeability measurements were carried out in
triplicate for each dextran-f MW.
X-ray photoelectron spectroscopy (XPS)
In order to quantitatively study the atomic composition, samples
of fresh capsules were washed three times with ultrapure water and
gradually lyophilized. Samples of lyophilized capsules were fixed
on a sample holder. The sample holder was inserted into the
chamber of an X-ray photoelectron spectrometer (Surface Science
Instruments, S-probe, Mountain View, CA). An aluminum anode
was used for generation of X-rays (10 kV, 22 mA) at a spot size of
25061000 mm. During the measurements, the pressure in the
spectrometer was approximately 1027 Pa. First, scans were
collected over the binding energy range of 1–1100 eV at low
resolution (150 eV pass energy). Next, we recorded at high
resolution (50 eV pass energy) C1s, N1s, and O1s peaks over a
20 eV binding energy range. The polymer content of the capsule’s
surface was expressed as a percentage of the total C, N, and O
content of the membrane.
Animal studies
Wild-type male Balb/c mice were purchased from Harlan
(Harlan, Horst, The Netherlands). The animals were fed standard
chow and water ad libitum. All animal experiments were
performed after receiving approval of the institutional Animal
Care Committee of the Groningen University. All animals
received animal care in compliance with the Dutch law on
Experimental Animal Care. The mice were sacrificed by cervical
dislocation.
Figure 1. Alginate-PEG454-b-PLL100 capsules a) before implantation and b) at one month after implantation. GMA-embedded
histological sections, Romanovsky-Giemsa staining, original magnification610.
doi:10.1371/journal.pone.0109837.g001
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Implantation and explanation of empty capsules
Capsules were injected into the peritoneal cavity with a 16 G
cannula via a small incision (3 mm) in the linea alba. The
abdomen was closed with a two-layer suture. The implanted
volume was always 0.5 mL as assessed in a syringe with
appropriate measure. The transplants contained at least 1000
capsules. The microcapsules were retrieved 1 month after
implantation by peritoneal lavage. Peritoneal lavage was per-
formed by infusing 2 mL KRH through a 3 mm midline incision
into the peritoneal cavity and subsequent aspiration of the KRH
containing the capsules. All surgical procedures were performed
under isoflurane anesthesia.
Histology
To assess the integrity of capsules before implantation, the
samples of capsules were meticulously inspected for the presence of
irregularities or defects in the capsule’s membranes by using a
dissection microscope.
To detect physical imperfections and to assess the composition
and degree of overgrowth after implantation, samples of adherent
capsules recovered by excision and samples of non-adherent
capsules were fixed in pre-cooled 2% paraformaldehyde, buffered
with 0.05 M phosphate in saline (pH 7.4), and processed for
(hydroxyethyl)methacrylate (HEMA) embedding [39]. Sections
were prepared at 2 mm, stained with Romanovsky-Giemsa stain
and applied for detecting imperfections in the capsule’s mem-
brane, for quantifying the composition of the overgrowth and
determining the number of capsules with and without overgrowth.
Different cell-types in the overgrowth were assessed by identifying
cells in the capsular overgrowth with the morphological charac-
teristics of monocytes/macrophages, lymphocytes, granulocytes,
fibroblasts, basophiles, erythrocytes, and multinucleated giant
cells. To confirm the adequacy of this approach, portions of
adherent and non-adherent capsules were frozen in precooled
isopropane as described in a previous study [17], sectioned at
5 mm, and processed for immunohistochemical staining and
quantification of the different cell types as previously described
[40]. The used monoclonal antibodies were: ED1 and ED2 against
monocytes and macrophages [41], HIS-40 against IgM bearing B-
lymphocytes [42], and R73 against CD3+ bearing T-lymphocytes
[43], In control sections we used PBS instead of the first stage
monoclonal antibody. Quantification of these cells types after
immunocytochemistry was compared with the assessments on the
basis of morphological markers and always gave similar results.
The degree of capsular overgrowth was quantified by expressing
the number of recovered capsules with overgrowth as the
percentage of the total number of recovered capsules for each
individual animal.
Statistical analysis
Values are expressed as mean 6 standard error of the mean
(SEM). Normal distribution of the data was confirmed using the
Kolmogorov-Smirnov test. As no normal distribution could be
demonstrated, we applied the nonparametric Mann Whitney-U
test. P-values,0.05 were considered to be statistically significant.
The n-values for the animal experiments were based on a
mandatory power analysis. The values were 4 mice per
experimental group, based on a type I error of 5% and a type II
error of 10%.
Figure 2. Kinetics of adsorption of the PEG454-b-PLL50 (N) and PEG454-b-PLL100 (m) diblock copolymer on a) the alginate gel and b)
the alginate gel pretreated for 10 minutes with PLL100.
doi:10.1371/journal.pone.0109837.g002
Figure 3. Illustration of a) alginate-PEG-b-PLL capsules (with-
out PLL100 pretreatment) and b) alginate-PLL-PEG-b-PLL
capsules (with PLL100 pretreatment).
doi:10.1371/journal.pone.0109837.g003
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Results
The host responses against alginate-capsules where the
PLL layer was completely substituted by PEG454-b-PLL100
to provide immunoprotection
Based on previous findings [24], we chose the long PEG454 for
the in vivo application because these long chains cannot easily
penetrate into the alginate matrix and will stay at the surface. The
positively charged PLL blocks are relatively small and will readily
penetrate the alginate matrix where the ammonium groups of PLL
will ionically interact with the carboxyl groups of alginate. To this
end, the two PEG-b-PLL diblock copolymers were allowed to
cross-link for one hour. This time period has found to be sufficient
to create capsules with a permeability that does not allow entry of
molecules larger than 120 kg/mol, which is considered to be an
immunoprotective threshold [24,31,44]. Before implantation all
capsules were meticulously microscopically inspected. Only perfect
capsules with no tails or other imperfections associated with host
responses were selected for implantation [45–47] (Figure 1a).
The capsules were implanted in the peritoneal cavity of balb/c
mice and retrieved after one month. Macroscopically, the capsules
with either an immunoprotective PEG454-b-PLL50 or PEG454-b-
PLL100 were found in one large clump around the place of
implantation. Examination by histology revealed that the capsules
were caught in thick layers of fibroblast and were adherent to each
other. This may be a sign of an unstable membrane in which
positively charged molecules instantly attract inflammatory cells
leading to heavy fibroblast overgrowth (Figure 1b). A series of
infrared studies revealed that the relatively short period of
incubation (i.e. 1 hour), which provides a permeability of 100–
120 kg/mol [24] with PEG454-b-PLLy (y = 50 or 100), was too
short to allow the formation of a stable membrane (see Figure 2a).
The fact that both PEG454-b-PLLy (y = 50 or 100) cannot
adequately substitute PLL in providing an immunoprotective
membrane does not imply that they cannot be used for other
purposes. The copolymers can be used for the formation of a
masking anti-biofouling layer on top of PLL. PEG-b-PLL
copolymers have been characterized as polymer with a low
immunogenic capacity as they do elicit minor immune activation
of nuclear factor NF-kB in THP-1 monocytes [24]. A prerequisite
as outlined above, is that the diblock copolymer chains should be
adequately bound to the matrix. For these reasons, the next step in
our study was to apply PEG-b-PLL copolymers on top of a
preexisting immunoprotective layer of proinflammatory PLL.
Prior to the copolymer treatment, PLL100 was applied to reduce
the permeability of the alginate beads. This was done according to
the principle illustrated in Figure 3. PLL100 efficiently reduces
permeability, but PLL100 does provoke strong host responses as
shown below. In order to determine the time period required to
build an effective copolymer layer on top of the alginate-PLL100
membrane, we applied FTIR. To this end, one to 1.5 mm thick
alginate layers deposited on silicon wafers were incubated in a
PLL100 solution for 10 minutes, measured by FTIR and subse-
quently exposed to the copolymer solution and measured again.
The kinetics of the adsorption was followed through the increase of
Figure 4. Confocal microscopy images after staining of the PEG blocks. a) Alginate-PLL100 capsules, b) alginate-PLL100-PEG454-b-
PLL50 capsules and c) alginate-PLL100-PEG454-b-PLL100 microcapsules. Original magnification 106.
doi:10.1371/journal.pone.0109837.g004
Figure 5. Viability of the insulin producing CM-cells encapsulated in a) alginate-PLL100 capsules, b) alginate-PLL100-PEG454-b-PLL50
capsules and c) alginate-PLL100-PEG454-b-PLL100 microcapsules after 5 days of culturing. The remnants and dead cells were still visible in
the periphery of the capsules.
doi:10.1371/journal.pone.0109837.g005
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the bands that correspond to symmetric and asymmetric C-H
stretching vibrations in the FTIR spectrum. Since methyl,
methylene, and methine groups do not participate in hydrogen
bonding, the position of the bands corresponding to these groups is
virtually not influenced by the chemical environment of the
measured substance [48]. Therefore, this region was considered as
the most reliable to study the quantity of the adsorbed PLL and/or
copolymers. The surface area of the C-H bands was determined,
reduced for the value which corresponds to C-H vibrations of the
alginate gel and plotted as a function of time (see Figure 2).
After the pretreatment of the calcium-alginate layers with
PLL100, FTIR analysis showed that diblock copolymer chains
could still interact and bind to the alginate gels as illustrated in
Figure 3b. Binding of copolymers to the alginate-PLL100 layer
started immediately, continued asymptotically and reached a
maximum value after approximately 25 hours for PEG454-b-
PLL100 and 50 hours for PEG454-b-PLL50 (Figure 2b). Conse-
quently, these time periods were taken as the minimum to achieve
a high concentration of copolymers on the capsules’ surface and to
form an anti-biofouling layer on top of the alginate-PLL100 layer.
In the present study we compared the capsules coated with the
diblock copolymers for one hour with capsules coated with PLL100
(10 minutes) and with PEG454-b-PLL50 for 50 hours. The reason
is that we took the saturation time periods and therefore made this
comparison. The alginate-PLL100-PEG454-b-PLLy (y = 50 or 100)
capsules were prepared by incubating alginate beads in the PLL100
solution for 10 min and subsequently in the copolymer solution for
approximately 50 hours. To confirm binding of copolymers to
PLL100-precoated alginate capsules, the staining of the PEG blocks
at the surface with antibodies directed against the end group of
these blocks (methoxy group) was performed. PLL100 capsules
were used as negative control. The presence of green fluorescence
on the alginate-PLL100-PEG454-b-PLLy (y = 50 or 100) microcap-
sules demonstrated successful adsorption of diblock copolymers on
the surface (Figure 4).
In order to determine whether long incubation times of
50 hours can influence the viability of cells, the insulin producing
CM-cells were encapsulated according to this new procedure.
CM-cells encapsulated in conventional control alginate-PLL100
capsules, that were exposed for only ten minutes to PLL, served as
control. The cell-containing capsules were subjected to live-dead
staining for studying by confocal microscopy after the encapsu-
lation procedure as well as after culturing for 5 days.. Figure 5
shows the results. The number of dead cells in the capsules was
always below 20% and was not different between the freshly
encapsulated cells and cells in capsules incubated for 5 days
(Table 1). As shown in the enclosed Movie S1 after 5 days of
culturing only the remnants of dead cells were still visible. The
remnants and dead cells were always in the periphery of the
capsules and were observed in all capsule types suggesting that
direct interaction with PLL rather than the incubation times is
responsible for death of these cells. The same results (data not
shown) were obtained for T84 cells which usually are very sensitive
for long times of serum deprivation.
The coating procedure had no influence on the permeability of
the capsules. The alginate-PLL100 capsules, as well as the 25 hours
PEG454-b-PLL100 and the 50 hours for PEG454-b-PLL50 capsules
were tested for permeability with fluorescent dextran with
molecular weights of 10, 20, 40, 70, 110, and 150 kg/mol. All
three capsule’s types were still allowing entry of dextran with a
molecular weight of 110 kg/mol but were impermeable for
dextran with a Mw of 150 kg/mol (Table 2 and Figure 6).
Uncoated, calcium alginate beads were permeable for all samples
Table 1. Percentage of dead CM-cells encapsulated in a) alginate-PLL100 capsules (10 minutes incubation), b) alginate-PLL100-
PEG454-b-PLL50 capsules (50 hours incubation) and c) alginate-PLL100-PEG454-b-PLL100 microcapsules (50 hours incubation)
immediately after encapsulation and after 5 days of culturing (n = 4).
Samples of capsules Dead CM-cells





Table 2. Permeability of the alginate-PLL100, alginate-PLL100-PEG454-b-PLL50 and alginate-PLL100-PEG454-b-PLL100 capsules
determined using dextran-f samples.
Dextran Samples, Molecular weight of dextran,
kg/mol Type of the alginate capsules (A)
A-PLL100 A-PLL100-PEG454-b-PLL50 A-PLL100-PEG454-b-PLL100
10 + + +
20 + + +
40 + + +
70 + + +
110 + + +
150 2 2 2
doi:10.1371/journal.pone.0109837.t002
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of dextran. This illustrated that the initial PLL100 incubation is the
diffusion-limiting step.
X-ray photoelectron spectroscopy confirms presence of
diblock copolymers at the surface
X-ray photoelectron spectroscopy (XPS) is a surface-sensitive
quantitative technique for studying elemental composition, chem-
ical, and electronic state of the elements in the material. This
technique provides information for the top 2 to 10 nm of any
analyzed material. XPS has been extensively used to study the
composition of the capsule’s surface [15,17,26,49]. To investigate
the elemental composition, capsules were analyzed by XPS [17].
The surface elemental composition of the alginate-PLL100 and
alginate-PLL100-PEG454-b-PLLy (y = 50 or 100) capsules is
presented in Table 3. The ratio of carbon to nitrogen (C/N) for
the surface of the PLL-microcapsules was 8.14, whereas the
theoretical C/N ratio for PLL is 3. This indicates that 2–10 nm
surface layer is composed of both alginate and PLL as shown in
our previous studies [17,49]. The C/N ratio for the surface of the
alginate-PLL100-PEG454-b-PLLy (y = 50 or 100) capsules is similar
to the theoretical C/N ratio of the corresponding copolymers.
Therefore, the XPS analysis confirmed that the surface of these
capsules is mainly composed of the diblock copolymers.
Host response against alginate-PLL100 and
alginate-PLL100-PEG454-b-PLL50 capsules
The last step in our study was to investigate whether the
copolymer layer, formed after up to 50 hours of cross-linking with
alginate-PLL100 was functional in vivo. We only applied the
PEG454-b-PLL50 in the in vivo study. Alginate-PLL100 capsules
(i.e. controls) and the alginate-PLL100-PEG454-b-PLL50 capsules
were implanted in the peritoneal cavity of balb/c mice. Before
implantation, the grafts (n = 4) were meticulously inspected to
ensure that they had a similar mechanical stability and had no
broken or imperfect capsules.
The alginate-PLL100 capsules without an anti-biofouling layer
provoked a very strong inflammatory response as expected. All
capsules were found to adhere to the surface of the abdominal
organs, which caused a low retrieval rate of the capsules
(Figure 7a). In two animals the capsules were found as clumps
on top of the liver and were completely caught in thick layers of
fibroconnective tissue. Histologically high numbers of macrophag-
es and fibroblasts were found. We also found multinucleated giant
cells but no T-cells or B-cells. The few alginate-PLL100 capsules
that escaped from the host response where mostly caught in the
fibrotic clumps.
This was different when the anti-biofouling layer of PEG454-b-
PLL50 was applied (Table 4). Upon retrieval, 80–100% of the
capsule grafts were recovered from the peritoneal cavity, whereas
only 2.565% of the alginate-PLL100 capsules were recovered (P,
0.01). The alginate-PLL100-PEG454-b-PLL50 capsules were mostly
Table 3. Elemental surface compositions of alginate-PLL100 and alginate-PLL100-PEG454-b-PLLy (y = 50 or 100) microcapsules and
theoretical atom % of PLL100 homopolymer and PEG454-b-PLLy (y = 50 or 100) diblock copolymers.
Capsules, alginate- C, % O, % N, % Ca, % Others (Including Na and Cl), % C/N ratio
PLL100 58.42 26.97 7.18 1.38 6.05 8.14
PLL-PEG454-b-PLL50 66.38 27.37 6.25 0 0 10.62
PLL-PEG454-b-PLL100 65.70 25.26 9.04 0 0 7.27
Theoretical atom % of
PLL 66.67 11.11 22.22 0 0 3.00
PEG 66.67 33.33 0 0 0 -
PEG454-b-PLL50 66.67 27.81 5.52 0 0 12.08
PEG454-b-PLL100 66.67 24.49 8.84 0 0 7.54
doi:10.1371/journal.pone.0109837.t003
Figure 6. Confocal microscopy images of alginate-PLL-PEG-b-PLL microcapsules after the addition of a) dextran of 110 kg/mol and
b) dextran of 150 kg/mol.
doi:10.1371/journal.pone.0109837.g006
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free-floating and did not adhere to the abdominal organs. The
capsules were found in between the intestines and clumping was
rarely observed [50]. The percentage of capsules with cellular
overgrowth with alginate-PLL100-PEG454-b-PLL50 capsules was
36.25627.87% whereas with alginate-PLL100 capsules it was
97.2565.5% (P,0.01) at one month after implantation. The
capsules’ surface was only rarely covered completely with the
cellular overgrowth. Mostly, just a few cells were adhered which is
usually interpreted as a local imperfection on the capsules’ surface.
The overgrowth was mainly composed of macrophages and a few
fibroblasts (Figure 7b). We found no T-cells or other cells of the
adaptive immune system on the capsules or on surrounding tissues
that were taken for biopsy.
Discussion
A combined physicochemical and biological approach is still
rarely implied in the encapsulation field [28]. The observation that
by using diblock copolymers as substitutes for PLL strong
inflammatory responses were induced while the diblock copoly-
mers applied on the top of the alginate-PLL100 surface reduced
inflammatory responses, illustrates the necessity of a multidisci-
plinary approach in understanding the chemical background of
host responses against microcapsules. Our work demonstrates that
some polymers such as PEG454-b-PLL50 or PEG454-b-PLL100 are
not applicable for creating immunoprotective membranes. The
relatively short incubation times required to create a membrane
impermeable for molecules above 100–120 kg/mol are not
sufficient to provide stable membranes. The same may hold true
for many other polymers suggested to substitute PLL [20–23].
In this study, only intermediate-G alginates were applied, as
only this type of alginate contains sufficient G-M blocks to bind
PLL [17,32]. The diblock copolymer had no effect on the cells in
the matrix as demonstrated with insulin producing CM-cells.
Moreover, the PEG-b-PLL copolymer has been characterized as a
unique polymer with a low immunogenic capacity [24], and PEG
is known to provide an anti-biofouling layer in cell microencap-
sulation [51–56]. Therefore, we did not immediately abandon its
application. Instead we studied whether the copolymer can form
an anti-biofouling layer on top of the capsules’ surface, which
should reduce host responses against capsule’s components.
However, before studying the application of the copolymers as
anti-biofouling layer on top of PLL100, we first did a chemical
analysis of the capsules’ surface and determined the requirements
for the optimal binding. Transmission FTIR study was applied to
determine the time-period required for optimal binding and
saturation. Elemental analysis of the capsules’ surface in combi-
nation with immunocytochemistry demonstrated the efficiency of
the bound copolymers to mask proinflammatory PLL. We found
that 50 hours of incubation were required to form an efficacious
layer on top of the PLL100. Such long incubation time-periods may
not be applicable for all cell types, but up to now all cells we
applied did survive and functioned when cultured for prolonged
periods in Krebs-Ringer-Hepes (KRH). KRH is a balanced salt
solution that was especially developed for encapsulation of cells
[33]. It is serum free but allows for survival of cells for prolonged
periods of time.
Figure 7. Explanted a) alginate-PLL100, (original magnification 106). Note the macrophages and fibroblasts. b) Alginate-PLL100-PEG454-b-
PLL50 microcapsules (original magnification 406). Only a portion of capsules had inflammatory cells at the surface. Note that the affected capsules in
most cases had adherence of a few or sometimes clumps of cells instead of complete coverage as in a). This suggests that local imperfections at the
capsule’s surface may be responsible for cell adhesion. All capsules were retrieved one month after implantation in the peritoneal cavity of balb/c
mice GMA-embedded histological sections, Romanovsky-Giemsa staining.
doi:10.1371/journal.pone.0109837.g007
Table 4. Recovery rates and percentage of alginate-PLL100 and alginate-PLL100–PEG454-b-PLL50 capsules with overgrowth, 1 month
after implantation in the peritoneal cavity of balb/c mice.
Type of capsules n Recovery, % Overgrowth, %
Alginate-PLL100 4 2.565 97.2565.5
Alginate-PLL100-PEG454-b-PLL50 4 95610 36.25627.87
doi:10.1371/journal.pone.0109837.t004
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The PEG454-b-PLL50 binding severely reduced the responses in
mice against the alginate-PLL100 surfaces. The vast majority of the
alginate-PLL100-PEG454-b-PLL50 capsules were free of any cell
adhesion and free-floating in the peritoneal cavity, whereas nearly
all alginate-PLL100 capsules without the copolymer were com-
pletely overgrown with macrophages and fibroblasts. Notably,
however, some attachment of inflammatory cells was still observed
on a portion of the alginate-PLL100-PEG454-b-PLL50 capsules.
This adhesion of cells was different from what we have previously
observed [15,57–60]. Complete coverage of capsule with inflam-
matory cells and fibroblasts, which is indicative for a foreign body
response to the capsules, was rarely observed. In most cases,
adhesion of groups of macrophages to specific parts of the
capsule’s surface was seen, suggesting that local imperfections were
responsible for immune activation [45,61]. We believe that spatial
differences in coating efficacy can be the cause of this type of cell
adhesion implying that the system may still be improved in spite of
the step-wise chemical approach. For sake of clarity, we counted
all the capsules with overgrowth irrespective of the degree of
overgrowth. Sometimes just one or two cells were found on the
capsules with the PEG454-b-PLL50 copolymer (Figure 7b). We
believe that these cells will not have an influence on the functional
survival of the cells in the capsules [45,61]. The data should
therefore be carefully interpreted. The overgrowth is not
necessarily having more consequences for cell survival than what
was observed in previous studies were around 10% of the capsules
were affected but infiltrated with large numbers of inflammatory
cells instead of the few cells we found on the affected capsules in
this study [44,45,62].
Creating an immunoprotective membrane with PLL without
causing an inflammatory response has been shown to be a pitfall in
many laboratories [27,63]. Variations in creating an efficacious
PLL-membrane that provides immunoprotection without host-
responses are one of the major factors responsible for the reported
lab-to-lab variations with microcapsules [11,28,44,49,60,64]. The
role of PLL in host responses has also been demonstrated in studies
that show that calcium alginate normally does not provoke a
response, but as soon as a polyamino acid is applied, strong
inflammatory responses arise [63]. Adequate binding of PLL on
the alginate matrix, which should result in formation of
superhelical cores of alginate around PLL, depends on several
crucial factors [14,29,65]. It is well recognized that alginate should
contain sufficient G-M residues to bind all proinflammatory PLL
[17,66]. A seemingly minor difference in G-M content can lead to
leakage of PLL in vivo with foreign body responses as a
consequence [17]. Another factor that is not often taken into
consideration is the porosity of the alginate-gel in relation to the
size of PLL chain. In our lab the 3.4% intermediate-G alginate
gels are commonly used to create an immunoprotective membrane
in combination with PLL of 22 to 24 kg/mol [15,17,49]. This
relatively large molecule will only bind to sodium-alginate residues
at the top 2–4 mm surface of the capsules [15,19,28]. Lower
alginate concentrations or smaller PLL molecules can cause
incomplete binding of PLL to the alginate core followed by leakage
or exposure of unbound PLL at the capsule’s surface in vivo with
eventually host-responses as a consequence [11,13,67]. As shown
here, anti-biofouling layers of the PEG454-b-PLL50 copolymer may
contribute to making PLL binding a less delicate process. Building
an efficacious antifouling layer requires however a long incubation
period of 50 hours, but it is rather simple as it involves only an
incubation step. The binding efficacy can easily be followed
through the increase of the bands that correspond to symmetric
and asymmetric C-H stretching vibrations in the FTIR spectrum.
The simple incubation step requires much less skills and
technologies than adequate binding of PLL which depends not
only on incubation with PLL but also on exchange of series of ions
[14]. The application of this anti-biofouling layer may reduce in
the enormous lab-to-lab variations that are considered to be a
major threat for progress in the field [17,29,68].
Our study should not be interpreted as a suggestion that PLL
binding is the only factor in host-responses against alginate-based
microcapsules. Other important issues are the degree of purity of
the alginates [16,26,28,65] and the type of alginates
[18,32,49,62,64]. Crude alginates contain not only polyphenols
but also pathogen associated molecular patterns that are potent
stimulators of the immune system [69,70]. Nowadays, only
ultrapure alginates are applied and intermediate-G alginates are
preferred over high-G alginates despite a better mechanical
stability of the high-G alginate gels [32,71–74]. In this study, only
pure alginates with no immunostimulatory capacity were applied
[24]. Our data showed that in spite of the extreme purity of
alginates, inflammatory responses against capsules still occur due
to presence of positively charged polyamino acids at the surface of
capsules that are not in the required confirmation [12,13].
Conclusions
PEG-b-PLL diblock copolymers may contribute to reduction of
host responses against alginate-PLL100 capsules by masking
proinflammatory PLL100 residues. As such, PEG-b-PLL diblock
copolymers are effective anti-biofouling molecules. Also, it was
demonstrated that PEG-b-PLL diblock copolymers are not
suitable as complete substitute for PLL because they provide
membranes with the corresponding permeability but are unstable
in vivo. Our study further illustrates the necessity of combining
physicochemical and biological means to understand the complex
interactions at the surface of microcapsules and the associated
biological responses.
Supporting Information
Movie S1 Viability of the insulin producing CM-cells
encapsulated in alginate-PLL100 capsules after 5 days of
culturing. After 5 days of culturing only the remnants of dead
cells were still visible. The remnants and dead cells were always in
the periphery of the capsules suggesting that direct interaction with
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